CNN: Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis Dupixent included in China’s list of overseas approved drugs that meet urgent clinical need Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the ... CNN: Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ... Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis.

Understanding the Context

It can be exhausting for a child to ... TribLIVE.com: Dupixent and cancer risks: What patients need to know about lymphoma concerns Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Key Insights

Dupixent and cancer risks: What patients need to know about lymphoma concerns